| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... The lancet oncology 13 (3), 239-246, 2012 | 6516 | 2012 |
| Screening for epidermal growth factor receptor mutations in lung cancer R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ... New England Journal of Medicine 361 (10), 958-967, 2009 | 3051 | 2009 |
| Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer J Wolf, T Seto, JY Han, N Reguart, EB Garon, HJM Groen, DSW Tan, ... New England Journal of Medicine 383 (10), 944-957, 2020 | 887 | 2020 |
| Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer BBS Zhou, M Peyton, B He, C Liu, L Girard, E Caudler, Y Lo, F Baribaud, ... Cancer cell 10 (1), 39-50, 2006 | 491 | 2006 |
| Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ AMC Dingemans, M Früh, A Ardizzoni, B Besse, C Faivre-Finn, ... Annals of Oncology 32 (7), 839-853, 2021 | 423 | 2021 |
| Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma A Prat, A Navarro, L Paré, N Reguart, P Galván, T Pascual, A Martínez, ... Cancer research 77 (13), 3540-3550, 2017 | 416 | 2017 |
| Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation R Porta, JM Sanchez-Torres, L Paz-Ares, B Massuti, N Reguart, C Mayo, ... European Respiratory Journal 37 (3), 624-631, 2011 | 411 | 2011 |
| Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer J Mazieres, B He, L You, Z Xu, AY Lee, I Mikami, N Reguart, R Rosell, ... Cancer research 64 (14), 4717-4720, 2004 | 361 | 2004 |
| Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non–small-cell lung cancer patients with EGFR mutations R Rosell, MA Molina, C Costa, S Simonetti, A Gimenez-Capitan, ... Clinical Cancer Research 17 (5), 1160-1168, 2011 | 360 | 2011 |
| Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells L You, B He, Z Xu, K Uematsu, J Mazieres, I Mikami, N Reguart, ... Oncogene 23 (36), 6170-6174, 2004 | 342 | 2004 |
| DNA repair and cisplatin resistance in non-small-cell lung cancer R Rosell, RVN Lord, M Taron, N Reguart Lung cancer 38 (3), 217-227, 2002 | 322 | 2002 |
| Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations B He, N Reguart, L You, J Mazieres, Z Xu, AY Lee, I Mikami, F McCormick, ... Oncogene 24 (18), 3054-3058, 2005 | 290 | 2005 |
| Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer M Provencio, E Nadal, JL González-Larriba, A Martínez-Martí, R Bernabé, ... New England Journal of Medicine 389 (6), 504-513, 2023 | 281 | 2023 |
| Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial N Karachaliou, C Mayo-De Las Casas, C Queralt, I De Aguirre, B Melloni, ... JAMA oncology 1 (2), 149-157, 2015 | 272 | 2015 |
| An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth L You, B He, Z Xu, K Uematsu, J Mazieres, N Fujii, I Mikami, N Reguart, ... Cancer research 64 (15), 5385-5389, 2004 | 239 | 2004 |
| Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression R Rosell, L Perez-Roca, JJ Sanchez, M Cobo, T Moran, I Chaib, ... PloS one 4 (5), e5133, 2009 | 238 | 2009 |
| Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ... The Lancet Respiratory Medicine 5 (5), 435-444, 2017 | 220 | 2017 |
| Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis M Duruisseaux, A Martínez-Cardús, ME Calleja-Cervantes, S Moran, ... The Lancet Respiratory Medicine 6 (10), 771-781, 2018 | 206 | 2018 |
| Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer: the phase 2 KEYNOTE-799 … SK Jabbour, KH Lee, N Frost, V Breder, DM Kowalski, T Pollock, ... JAMA oncology 7 (9), 1351-1359, 2021 | 204 | 2021 |
| Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study F Blackhall, K Jao, L Greillier, BC Cho, K Penkov, N Reguart, M Majem, ... Journal of Thoracic Oncology 16 (9), 1547-1558, 2021 | 201 | 2021 |
Jordi RemonHospital de MataróE-mail megerősítve itt: csdm.cat